Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Eviplera
Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-214409 · Präparat HOS-155326
Where possible, alternatives such
as azithromycin should be
considered.
ANTICONVULSANTS
Carbamazepine Interaction not studied with any Eviplera must not be used in
Oxcarbazepine components of Eviplera. combination with these
Phenobarbital anticonvulsants as
Phenytoin co-administration may cause
significant decreases in rilpivirine
plasma concentrations (induction
of CYP3A enzymes). This may
result in loss of therapeutic effect
of Eviplera (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) azithromycin (HOS-088112) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage 893ac1e5a66801c81f451a610bc8f96885b829c98416f54003025bf179b89f20 · Zeichen 25538–26671 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 2 mg film-coated tablets Fycompa 4 mg film-coated tablets Fycompa 6 mg film-coated tablets Fycompa 8 mg film-coated tablets Fycompa 10 mg film-coated tablets Fycompa 12 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-125858 · Präparat HOS-096179
AED Influence of AED on Fycompa Influence of Fycompa on AED
coadministered concentration concentration
Carbamazepine 3 fold decrease <10% decrease
Clobazam No influence <10% decrease
Clonazepam No influence No influence
Lamotrigine No influence <10% decrease
Levetiracetam No influence No influence
Oxcarbazepine 2 fold decrease 35% increase 1)
Phenobarbital 20% decrease No influence
Phenytoin 2 fold decrease No influence
Topiramate 20% decrease No influence
Valproic Acid No influence <10% decrease
Zonisamide No influence No influence
1) Active metabolite monohydroxycarbazepine was not assessed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 647b74f1f5a644667e9a8063823957e8fd2e4109c0c3dd9c6238f2d38b637f3d · Zeichen 1607–2679 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 2 mg film-coated tablets Fycompa 4 mg film-coated tablets Fycompa 6 mg film-coated tablets Fycompa 8 mg film-coated tablets Fycompa 10 mg film-coated tablets Fycompa 12 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-125862 · Präparat HOS-096179
Based on the results from the population pharmacokinetic analysis of patients with partial-onset
seizures and patients with primary generalised tonic-clonic seizures the total clearance of Fycompa
was increased when co-administered with carbamazepine (3-fold), and phenytoin or oxcarbazepine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 27598b6d3cd641af3c1e06ab4b51677dc6f0989886ab6dce1d8589e7560e939f · Zeichen 2681–2972 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 2 mg film-coated tablets Fycompa 4 mg film-coated tablets Fycompa 6 mg film-coated tablets Fycompa 8 mg film-coated tablets Fycompa 10 mg film-coated tablets Fycompa 12 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-125865 · Präparat HOS-096179
Perampanel was found to decrease the clearance of oxcarbazepine by 26%. Oxcarbazepine is rapidly
metabolised by cytosolic reductase enzyme to the active metabolite, monohydroxycarbazepine. The
effect of perampanel on monohydroxycarbazepine concentrations is not known.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 06ad83edb909fefd5543090bb9adbc5df80d117812394ded69187daae495b38c · Zeichen 3774–4042 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 0.5 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 29–30
HOS-125902 · Präparat HOS-096179
29
AED Influence of AED on Fycompa Influence of Fycompa on AED
coadministered concentration concentration
Carbamazepine 3 fold decrease <10% decrease
Clobazam No influence <10% decrease
Clonazepam No influence No influence
Lamotrigine No influence <10% decrease
Levetiracetam No influence No influence
Oxcarbazepine 2 fold decrease 35% increase 1)
Phenobarbital 20% decrease No influence
Phenytoin 2 fold decrease No influence
Topiramate 20% decrease No influence
Valproic Acid No influence <10% decrease
Zonisamide No influence No influence
1) Active metabolite monohydroxycarbazepine was not assessed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 27257b38863890a7e9dcd5ec83e5495cfc50cf21047cba94476f502d1cb8f8f6 · Zeichen 1653–2734 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 0.5 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 30
HOS-125903 · Präparat HOS-096179
Based on the results from the population pharmacokinetic analysis of patients with partial-onset
seizures and patients with primary generalised tonic-clonic seizures the total clearance of Fycompa
was increased when co-administered with carbamazepine (3-fold), and phenytoin or oxcarbazepine
(2-fold), which are known inducers of enzymes of metabolism (see section 5.2). This effect should be
taken into account and managed when adding or withdrawing these anti-epileptic drugs from a
patient’s treatment regimen. Clonazepam, levetiracetam, phenobarbital, topiramate, zonisamide,
clobazam, lamotrigine and valproic acid did not affect to a clinically relevant manner the clearance of
Fycompa.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 0082e100157a5b8d067c8c128173d1d009cc83c573888e5b8dcb2b89cb2beac5 · Zeichen 2736–3428 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 0.5 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 30
HOS-125905 · Präparat HOS-096179
Perampanel was found to decrease the clearance of oxcarbazepine by 26%. Oxcarbazepine is rapidly
metabolised by cytosolic reductase enzyme to the active metabolite, monohydroxycarbazepine. The
effect of perampanel on monohydroxycarbazepine concentrations is not known.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 06ad83edb909fefd5543090bb9adbc5df80d117812394ded69187daae495b38c · Zeichen 3772–4040 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-129163 · Präparat HOS-096689
8
Darunavir/ritonavir Dolutegravir No dose adjustment is necessary.
AUC 22%
Cmax 11%
C24 38%
(induction of UGT1A1 and
CYP3A enzymes)
Lopinavir/ritonavir Dolutegravir No dose adjustment is necessary.
AUC 4%
Cmax 0%
C24 6%
Other Antiviral agents
Daclatasvir Dolutegravir Daclatasvir did not change dolutegravir plasma
AUC 33% concentration to a clinically relevant extent.
Cmax 29% Dolutegravir did not change daclatasvir plasma
C 45% concentration. No dose adjustment is necessary.
Daclatasvir
Other agents
Potassium channel blocker
Fampridine (also Fampridine Co-administration of dolutegravir has the potential
known as to cause seizures due to increased fampridine
dalfampridine) plasma concentration via inhibition of OCT2
transporter; co-administration has not been studied.
Fampridine co-administration with dolutegravir is
contraindicated.
Anticonvulsants
Carbamazepine Dolutegravir The recommended adult dose of dolutegravir is 50
AUC 49% mg twice daily when co-administered with
Cmax 33% carbamazepine. In paediatric patients the weight-
C 73% based once daily dose should be administered
twice daily. Alternatives to carbamazepine should
be used where possible for INI resistant patients.
Oxcarbazepine Dolutegravir The recommended adult dose of dolutegravir is 50
Phenytoin (Not studied, decrease mg twice daily when co-administered with these
Phenobarbital expected due to induction of metabolic inducers. In paediatric patients the
UGT1A1 and CYP3A weight-based once daily dose should be
enzymes, a similar reduction administered twice daily. Alternative
in exposure as observed combinations that do not include these metabolic
with carbamazepine is inducers should be used where possible in INI-
expected) resistant patients.
Azole anti-fungal agents
Ketoconazole Dolutegravir No dose adjustment is necessary. Based on data
Fluconazole (Not studied) from other CYP3A4 inhibitors, a marked increase
Itraconazole is not expected.
Posaconazole
Voriconazole
Herbal products
St. John’s wort Dolutegravir The recommended adult dose of dolutegravir is 50
(Not studied, decrease mg twice daily when co-administered with St.
expected due to induction of John’s wort. In paediatric patients the weight-
UGT1A1 and CYP3A based once daily dose should be administered
enzymes, a similar reduction twice daily. Alternative combinations that do not
in exposure as observed include St. John’s wort should be used where
with carbamazepine is possible in INI-resistant patients.
expected)
Antacids and supplements
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) daclatasvir (HOS-119742) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) voriconazole (HOS-084524) itraconazole (HOS-084516) dalfampridine (HOS-124191) fluconazole (HOS-087945) darunavir (HOS-086181) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) potassium (HOS-086929) phenytoin (HOS-084531) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage 7146ae3c08ab0159cbd699143845d13f9721ca0ad65d42e769709558e2d4148f · Zeichen 9118–13250 im Abschnitt
Wechselwirkungen · Tivicay
Tivicay 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 38–39
HOS-129200 · Präparat HOS-096689
38
Lopinavir/ritonavir Dolutegravir No dose adjustment is necessary.
AUC 4%
Cmax 0%
C24 6%
Other Antiviral agents
Daclatasvir Dolutegravir Daclatasvir did not change dolutegravir plasma
AUC 33% concentration to a clinically relevant extent.
Cmax 29% Dolutegravir did not change daclatasvir plasma
C 45% concentration. No dose adjustment is necessary.
Daclatasvir
Other agents
Potassium channel blocker
Fampridine (also Fampridine Co-administration of dolutegravir has the potential
known as to cause seizures due to increased fampridine
dalfampridine) plasma concentration via inhibition of OCT2
transporter; co-administration has not been studied.
Fampridine co-administration with dolutegravir is
contraindicated.
Anticonvulsants
Carbamazepine Dolutegravir The recommended adult dose of dolutegravir
AUC 49% should be given twice daily when co-administered
Cmax 33% with carbamazepine. In paediatric patients the
C 73% weight-based once daily dose should be
administered twice daily. Alternatives to
carbamazepine should be used where possible for
INI resistant patients.
Oxcarbazepine Dolutegravir The recommended adult dose of dolutegravir
Phenytoin (Not studied, decrease should be given twice daily when co-administered
Phenobarbital expected due to induction of with these metabolic inducers. In paediatric
UGT1A1 and CYP3A patients the weight-based once daily dose should
enzymes, a similar reduction be administered twice daily. Alternative
in exposure as observed combinations that do not include these metabolic
with carbamazepine is inducers should be used where possible in INI-
expected) resistant patients.
Azole anti-fungal agents
Ketoconazole Dolutegravir No dose adjustment is necessary. Based on data
Fluconazole (Not studied) from other CYP3A4 inhibitors, a marked increase
Itraconazole is not expected.
Posaconazole
Voriconazole
Herbal products
St. John’s wort Dolutegravir The recommended adult dose of dolutegravir
(Not studied, decrease should be given twice daily when co-administered
expected due to induction of with St. John’s wort. In paediatric patients the
UGT1A1 and CYP3A weight-based once daily dose should be
enzymes, a similar reduction administered twice daily. Alternative combinations
in exposure as observed that do not include St. John’s wort should be used
with carbamazepine is where possible in INI-resistant patients.
expected)
Antacids and supplements
Magnesium/ Dolutegravir Magnesium/ aluminium-containing antacid should
aluminium-containing AUC 74% be taken well separated in time from the
antacid Cmax 72% administration of dolutegravir (minimum 2 hours
(Complex binding to after or 6 hours before).
polyvalent ions)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) daclatasvir (HOS-119742) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) voriconazole (HOS-084524) itraconazole (HOS-084516) dalfampridine (HOS-124191) fluconazole (HOS-087945) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) potassium (HOS-086929) magnesium (HOS-085165) phenytoin (HOS-084531) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:54:00Z · SHA-256 49ffb99144edc826feca26a0b941946b69a295b5c67e5f5fd79358277916c087 · Passage b1f6422443cc14d5f9a656df820bb5371607b232b50be9270e4f54627fc6d01d · Zeichen 9496–13843 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-129263 · Präparat HOS-096703
11
Antimycobacterials
Rifampicin/Dolutegravir Dolutegravir ↓ The dose of dolutegravir is 50 mg twice
AUC ↓ 54% daily when co-administered with
Cmax ↓ 43% rifampicin. As Triumeq is a fixed dose
Cτ ↓ 72% tablet, an additional 50 mg tablet of
(induction of UGT1A1 dolutegravir should be administered,
and CYP3A enzymes) approximately 12 hours after Triumeq
for the duration of the rifampicin co-
administration (a separate preparation of
dolutegravir is available for this dose
adjustment, see section 4.2).
Rifabutin Dolutegravir ↔ No dose adjustment is necessary.
AUC ↓ 5%
Cmax ↑ 16%
Cτ ↓ 30%
(induction of UGT1A1
and CYP3A enzymes)
Anticonvulsants
Carbamazepine/Dolutegravir Dolutegravir ↓ The recommended dose of dolutegravir
AUC ↓ 49% is 50 mg twice daily when co-
Cmax ↓ 33% administered with carbamazepine. As
Cτ ↓ 73% Triumeq is a fixed dose tablet, an
additional 50 mg tablet of dolutegravir
should be administered, approximately
12 hours after Triumeq for the duration
of the carbamazepine co-administration
(a separate preparation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Phenobarbital/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
Phenytoin/Dolutegravir (Not studied, decrease is 50 mg twice daily when co-
Oxcarbazepine/Dolutegravir expected due to induction administered with these metabolic
of UGT1A1 and CYP3A inducers. As Triumeq is a fixed dose
enzymes, a similar tablet, an additional 50 mg tablet of
reduction in exposure as dolutegravir should be administered,
observed with approximately 12 hours after Triumeq
carbamazepine is for the duration of the co-administration
expected) with these metabolic inducers (a separate
preparation of dolutegravir is available
for this dose adjustment, see section
4.2).
Antihistamines (histamine H2 receptor antagonists)
Ranitidine Interaction not studied. No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) histamine (HOS-088516) ranitidine (HOS-085660) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage c667a478669bd5d7bf1481bff4152a60605199708e7c92778db166c77cf6e33c · Zeichen 16252–19999 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 49
HOS-129358 · Präparat HOS-096703
Phenobarbital/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
Phenytoin/Dolutegravir (Not studied, decrease should be adjusted when co-
Oxcarbazepine/Dolutegravir expected due to induction administered with these metabolic
of UGT1A1 and CYP3A inducers.
enzymes, a similar
reduction in exposure as Dosing recommendations are provided
observed with in Table 2 (see section 4.2)
carbamazepine is
expected)
Antihistamines (histamine H2 receptor antagonists)
Ranitidine Interaction not studied. No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) histamine (HOS-088516) ranitidine (HOS-085660) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 377acffb9770a7db982e8e184dd5622d08989e157d6cb396dd8e98806885ed5e · Zeichen 15553–16394 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 400 mg film-coated tablets Sovaldi 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-129766 · Präparat HOS-096803
Medicinal products that are strong P-gp inducers in the intestine (carbamazepine, phenobarbital,
phenytoin, rifampicin and St. John’s wort) may significantly decrease sofosbuvir plasma concentration
leading to reduced therapeutic effect of Sovaldi and thus are contraindicated with Sovaldi (see
section 4.3). Medicinal products that are moderate P-gp inducers in the intestine (e.g. modafinil,
oxcarbazepine and rifapentine) may decrease sofosbuvir plasma concentration leading to reduced
therapeutic effect of Sovaldi. Co-administration with such medicinal products is not recommended
with Sovaldi (see section 4.4). Co-administration of Sovaldi with medicinal products that inhibit P-gp
and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma
concentration, thus Sovaldi may be co-administered with P-gp and/or BCRP inhibitors. Sofosbuvir and
GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of
medicinal products that are substrates of these transporters.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage f0890cc7e05936c62d3d2c7cc128981d568e4b4dd49bd6df59189570ec1ad636 · Zeichen 1009–2049 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 400 mg film-coated tablets Sovaldi 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-129780 · Präparat HOS-096803
(Induction of P-gp)
Oxcarbazepine Interaction not studied. Co-administration of Sovaldi with oxcarbazepine is
Expected: expected to decrease the concentration of
↓ Sofosbuvir sofosbuvir, leading to reduced therapeutic effect of
↔ GS-331007 Sovaldi. Such co-administration is not
recommended (see section 4.4).
(Induction of P-gp)
ANTIMYCOBACTERIALS
Rifampicinf Sofosbuvir Sovaldi is contraindicated with rifampicin (see
(600 mg single dose) ↓ Cmax 0.23 (0.19, 0.29) section 4.3).
↓ AUC 0.28 (0.24, 0.32)
Cmin (NA)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage ba6ce14d8aad4b4fa73251278f14228015b38b9f9ddfe38016535658d7f5c156 · Zeichen 5846–6678 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 150 mg coated granules in sachet Sovaldi 200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 39
HOS-129837 · Präparat HOS-096803
Medicinal products that are strong P-gp inducers in the intestine (carbamazepine, phenobarbital,
phenytoin, rifampicin and St. John’s wort) may significantly decrease sofosbuvir plasma concentration
leading to reduced therapeutic effect of Sovaldi and thus are contraindicated with Sovaldi (see
section 4.3). Medicinal products that are moderate P-gp inducers in the intestine (e.g. modafinil,
oxcarbazepine and rifapentine) may decrease sofosbuvir plasma concentration leading to reduced
therapeutic effect of Sovaldi. Co-administration with such medicinal products is not recommended
with Sovaldi (see section 4.4). Co-administration of Sovaldi with medicinal products that inhibit P-gp
and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma
concentration, thus Sovaldi may be co-administered with P-gp and/or BCRP inhibitors. Sofosbuvir and
GS-331007 are not inhibitors of P-gp and BCRP and thus are not expected to increase exposures of
medicinal products that are substrates of these transporters.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage f0890cc7e05936c62d3d2c7cc128981d568e4b4dd49bd6df59189570ec1ad636 · Zeichen 1009–2049 im Abschnitt
Wechselwirkungen · Sovaldi
Sovaldi 150 mg coated granules in sachet Sovaldi 200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 40
HOS-129849 · Präparat HOS-096803
(Induction of P-gp)
Oxcarbazepine Interaction not studied. Co-administration of Sovaldi with oxcarbazepine is
Expected: expected to decrease the concentration of
↓ Sofosbuvir sofosbuvir, leading to reduced therapeutic effect of
↔ GS-331007 Sovaldi. Such co-administration is not
recommended (see section 4.4).
(Induction of P-gp)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-22T14:59:00Z · SHA-256 66b8a9d8a664c3fd4fadbfdcf1cd8c6e93c3430d5e235cfa78b2847b24a28727 · Passage 4e257524d760b89ba107b50029aba54e09d327d80c37c70b1771152b45d75d3b · Zeichen 5929–6506 im Abschnitt
Wechselwirkungen · Intuniv
Intuniv 1 mg prolonged-release tablets Intuniv 2 mg prolonged-release tablets Intuniv 3 mg prolonged-release tablets Intuniv 4 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-131085 · Präparat HOS-097005
8
Moderate CYP3A4/5 Strong CYP3A4/5 inhibitors CYP3A4 inducers
inhibitors
Crizotinib Indinavir Etravirine
Diltiazem Itraconazole Modafinil
Erythromycin Ketoconazole Nevirapine
Fluconazole Posaconazole Oxcarbazepine
Fosamprenavir Ritonavir Phenobarbital
Imatinib Saquinavir Phenytoin
Verapamil Suboxone Primidone
Grapefruit juice Telaprevir Rifabutin
Telithromycin Rifampicin
St. John’s wort
See section 4.2 for further dosing recommendations
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) phenobarbital (HOS-085617) ketoconazole (HOS-084513) modafinil (HOS-090546) crizotinib (HOS-116818) rifabutin (HOS-086262) etravirine (HOS-088088) grapefruit juice (HOS-088787) imatinib (HOS-110212) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) erythromycin (HOS-084514) nevirapine (HOS-088064) oxcarbazepine (HOS-110224) fosamprenavir (HOS-086182) ritonavir (HOS-084521) phenytoin (HOS-084531) posaconazole (HOS-085622) primidone (HOS-090551) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T16:10:00Z · SHA-256 b225f42374a72478897a7ffe5fe45a28ed820ad0d048d0ca17875afae195379b · Passage 83e1890b9137e3eea77358af69aa1280189cb4e822259f47a5be466cc4048489 · Zeichen 3321–4331 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-132193 · Präparat HOS-097208
Medicinal products that are strong P-gp inducers (carbamazepine, phenobarbital, phenytoin,
rifampicin, rifabutin and St. John’s wort) may significantly decrease ledipasvir and sofosbuvir plasma
concentrations leading to reduced therapeutic effect of ledipasvir/sofosbuvir and thus are
contraindicated with Harvoni (see section 4.3). Medicinal products that are moderate P-gp inducers in
the intestine (e.g. oxcarbazepine) may decrease ledipasvir and sofosbuvir plasma concentrations
leading to reduced therapeutic effect of Harvoni. Co-administration with such medicinal products is
not recommended with Harvoni (see section 4.4). Co-administration with medicinal products that
inhibit P-gp and/or BCRP may increase ledipasvir and sofosbuvir plasma concentrations without
increasing GS-331007 plasma concentration; Harvoni may be co-administered with P-gp and/or
BCRP inhibitors. Clinically significant medicinal product interactions with ledipasvir/sofosbuvir
mediated by CYP450s or UGT1A1 enzymes are not expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 09975f2db8b4d9a562dc23e80b212478889614bfb07c543d7c56c6b671d735d9 · Zeichen 572–1588 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-132213 · Präparat HOS-097208
10
Medicinal product by Effects on medicinal Recommendation concerning co-administration
therapeutic areas product levels. with Harvoni
Mean ratio (90%
confidence interval) for
AUC, Cmax, Cmina, b
Oxcarbazepine Interaction not studied. Co-administration of Harvoni with oxcarbazepine is
Expected: expected to decrease the concentration of ledipasvir
↓ Ledipasvir and sofosbuvir leading to reduced therapeutic effect
↓ Sofosbuvir of Harvoni. Such co-administration is not
↔ GS-331007 recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 6d8d3948958e70b7b9f70c75a79c444fdabf7326ed90f92ef75073c0632e721f · Zeichen 9838–10727 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 33.75 mg/150 mg coated granules in sachet Harvoni 45 mg/200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 46
HOS-132302 · Präparat HOS-097208
Medicinal products that are strong P-gp inducers (carbamazepine, phenobarbital, phenytoin,
rifampicin, rifabutin and St. John’s wort) may significantly decrease ledipasvir and sofosbuvir plasma
concentrations leading to reduced therapeutic effect of ledipasvir/sofosbuvir and thus are
contraindicated with Harvoni (see section 4.3). Medicinal products that are moderate P-gp inducers in
the intestine (e.g. oxcarbazepine) may decrease ledipasvir and sofosbuvir plasma concentrations
leading to reduced therapeutic effect of Harvoni. Co-administration with such medicinal products is
not recommended with Harvoni (see section 4.4). Co-administration with medicinal products that
inhibit P-gp and/or BCRP may increase ledipasvir and sofosbuvir plasma concentrations without
increasing GS-331007 plasma concentration; Harvoni may be co-administered with P-gp and/or
BCRP inhibitors. Clinically significant medicinal product interactions with ledipasvir/sofosbuvir
mediated by CYP450s or UGT1A1 enzymes are not expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 09975f2db8b4d9a562dc23e80b212478889614bfb07c543d7c56c6b671d735d9 · Zeichen 572–1588 im Abschnitt
Wechselwirkungen · Harvoni
Harvoni 33.75 mg/150 mg coated granules in sachet Harvoni 45 mg/200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 49
HOS-132320 · Präparat HOS-097208
(Induction of P-gp)
Oxcarbazepine Interaction not studied. Co-administration of Harvoni with oxcarbazepine is
Expected: expected to decrease the concentration of ledipasvir
↓ Ledipasvir and sofosbuvir leading to reduced therapeutic effect
↓ Sofosbuvir of Harvoni. Such co-administration is not
↔ GS-331007 recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 750356f87f742a8e0f07b6c9216268e1cc4f57615fe903b20caaf1b8b7c72c31 · Zeichen 10251–10800 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.